Trial Profile
A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Debamestrocel (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Brainstorm Cell Therapeutics
- 30 Mar 2023 According to a Brainstorm Cell Therapeutics media release, data from this study were presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
- 01 Jan 2023 Preliminary results (n=18) assessing the safety and efficacy of three intrathecal cell treatments in progressive multiple sclerosis patients, published in the Multiple Sclerosis Journal.
- 20 Oct 2022 According to a Brainstorm Cell Therapeutics media release, data from this study will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS),